AstraZenca Pharma India

ASTRAZEN

₹ 5,259.55

₹ 126.70

2.46%

AstraZenca Pharma India
Market Sentiment

Timeline	Returns	Volume
Daily	-	-
Weekly	-3.23%	1,20,371
Monthly	-2.57%	2,95,991

AstraZenca Pharma India
Performance

DATA

CHART

Timeline	Daily	Weekly	Monthly
ASTRAZEN	-	-3.23%	-2.57%
Index	-	-1.46%	-2.67%
Peer Avg.	-	-3.57%	-2.19%

*Avg of index constituents

AstraZenca Pharma India
Fundamentals

DATA

CHART

Timeline	PE	PB	EV/EBIDTA	ROE	ROCE	Div. Yield
ASTRAZEN	103.71	12.54	58.89	12.78	17.36	0.28
Index	36.20	6.77	17.25	17.89	19.69	1.20
Peer Avg.	35.31	3.95	12.55	16.53	7.42	2.36

*Avg of index constituents

AstraZenca Pharma India
Key Metrics

DATA

CHART

Metrics	Sales Growth	Profit Growth	ROE	ROCE
FY '21-22	-0.98%	-33.98%	12.78	17.36
FY '20-21	-2.19%	29.21%	22.83	31.24
FY '19-20	14.21%	32.62%	21.83	34.61

AstraZenca Pharma India
Shareholding Pattern

Promoters : 75%

FII : 2.38%

DII : 1.19%

Public : 21.43%

Others : 0%

AstraZenca Pharma India
Profit & Loss

DATA

CHART

Metrics	Sales	Expenditure	EBITDA	PAT
FY '21-22	805.60	719.42	100.94	61.60
FY '20-21	813.56	678.09	148.31	93.30
FY '19-20	831.81	711.11	133.69	72.21

All values are in crores

AstraZenca Pharma India
Peer Comparison

DATA

CHART

Metrics	Sales	Expenditure	EBITDA	PAT
ASTRAZEN	805.60	719.42	100.94	61.60
TEJASNET	549.87	630.89	-37.75	-63.22
GODREJAGRO	7,244.94	6,667.83	670.30	364.57

All values are in crores

AstraZenca Pharma India
Similar Stocks

Glaxosmithkline Pharmaceuticals

GLAXO

₹ 1,972.30

- ₹ 3.60

-0.18%

AstraZenca Pharma India Share Price

AstraZeneca Pharma India Limited is an Indian biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolic; oncology and respiratory diseases. The company operates through the healthcare segment. The company manufactures, markets and distributes pharmaceuticals and provides clinical research services to a foreign group company. Its therapeutic offering in the CVRM business includes Forxiga (Dapagliflozin) in heart failure and chronic kidney disease. Its approvals in the oncology business include Imfinz (Durvalumab) for the treatment of bile duct carcinoma and Lynparza (Olaparib) for early breast cancer. The company has a range of oral diabetes medications that fall into two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The company's DPP4 offering consists of the Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metform) brands.

AstraZenca Pharma India FAQs

How to Buy AstraZenca Pharma India Share?

To purchase AstraZenca Pharma India shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for AstraZenca Pharma India (ticker symbol: astrazen) on the trading platform provided by your broker and purchase the shares.

What's AstraZenca Pharma India share price today?

The stock price of AstraZenca Pharma India as of 10 May 2024 is ₹5,259.55

What is the Market Cap of AstraZenca Pharma India?

Market capitalisation represents the total market value of a company's outstanding shares. As of 10 May 2024, AstraZenca Pharma India (ticker symbol: astrazen) has a market capitalisation of approximately ₹87,87,62,50,000.00

What is the PE and PB ratio of AstraZenca Pharma India?

AstraZenca Pharma India Ltd's price-to-book ratio as of 10 May 2024 is 12.540485, reflecting the market's valuation compared to its asset value. As of 10 May 2024, the trailing twelve months P/E (price-to-earnings) ratio is 103.71144, indicating the market values the company at around ₹103.71 for every ₹1 of earnings

What is the 52 Week High and Low of AstraZenca Pharma India Share?

AstraZenca Pharma India Ltd (astrazen) hit its 52-week high at ₹7,220.95, and its 52-week low at { ₹3,125.00}.